1 |
Albain KS, Crowley JJ, LeBlanc M, et al (1990). Determinants of improved outcome in small-cell lung cancer: an analysis of the 2, 580-patient Southwest Oncology Group data base. J Clin Oncol, 8, 1563-74.
|
2 |
Cristofanilli M, Budd GT, Ellis MJ, et al (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med, 351, 781-91.
DOI
ScienceOn
|
3 |
Alix-Panabieres C, Riethdorf S, Pantel K (2008). Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res, 14, 5013-21.
DOI
|
4 |
American Cancer Society (2009). Cancer facts and figures 2009. Atlanta: American Cancer Society.
|
5 |
Cohen SJ, Punt CJA, Iannotti N, et al (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol, 26, 3213-21.
DOI
ScienceOn
|
6 |
de Bono JS, Scher HI, Montgomery RB, et al (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res, 14, 6302-9.
DOI
ScienceOn
|
7 |
Foster NR, Mandrekar SJ, Schild SE, et al (2009). Prognostic factors differ by tumor stage for small cell lung cancer. Cancer, 115, 2721-31.
DOI
|
8 |
Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44.
DOI
ScienceOn
|
9 |
Hiltermann TJN, Pore MM, Van den Berg A, et al (2012). Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol, 23, 2937-42.
DOI
ScienceOn
|
10 |
Horner MJ, Ries LAG, Krapcho M (2009). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Based on November 2008 SEER submission data, posted to the SEER website.
|
11 |
Igawa S, Gohda K, Fukui T, et al (2014). Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett, 7, 1469.
|
12 |
Hou JM, Krebs MG, Lancashire L, et al (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol, 30, 525-32.
DOI
|
13 |
Hou JM, Greystoke A, Lancashire L, et al (2009). Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol, 175, 808-16.
DOI
|
14 |
Huang J, Wang K, Xu J, et al (2013). Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PloS one, 8, 78070.
DOI
|
15 |
Kato Y, Ferguson TB, Bennett DE et al (1969). Oat cell carcinoma of the lung. A review of 138 cases. Cancer, 23, 517-24.
DOI
|
16 |
Krebs MG, Sloane R, Priest L, et al (2011). Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol, 29, 1556-63.
DOI
|
17 |
Ma XL, Li YY, Zhang J, et al (2014). Prognostic role of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 6015.
DOI
|
18 |
Ma XL, Xiao ZL, Liu L, et al (2012). Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev, 13, 1137-44.
DOI
ScienceOn
|
19 |
Naito T, Tanaka F, Ono A, et al (2012). Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol, 7, 512-9.
DOI
|
20 |
Normanno N, Rossi A, Morabito A, et al (2014). Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer, 85, 314-9.
DOI
|
21 |
Shi W L, Li J, Du Y J, et al (2013). CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients. Med Oncol, 30, 1-8.
|
22 |
Oshita F, Sekiyama A, Suzuki R, et al (2003). Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by promoter methylation and silencing of the retinoic acid receptor-beta. Oncol Rep, 10, 105-8.
|
23 |
Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
DOI
ScienceOn
|
24 |
Rolle A, Gunzel R, Pachmann U et al (2005). Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC (R) is a predictor for relapse: A preliminary report. World J Surg Oncol, 3, 18.
DOI
|
25 |
Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. Ca-Cancer J Clin, 63, 11-30.
DOI
ScienceOn
|
26 |
Takada M, Fukuoka M, Kawahara M et al (2002). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol, 20, 3054-60.
DOI
ScienceOn
|
27 |
Tanaka F, Yoneda K, Kondo N, et al (2009). Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res, 15, 6980-6.
DOI
|
28 |
Wu C, Hao H, Li L, et al (2009). Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol, 4, 30-6.
DOI
|
29 |
Turker I, Uyeturk U, Sonmez OU, et al (2013). Detection of circulating tumor cells in breast cancer patients: prognostic predictive role. Asian Pac J Cancer Prev, 14, 1601-7.
DOI
|
30 |
Turrisi A T, Kim K, Blum R, et al (1999). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med, 340, 265-71.
DOI
ScienceOn
|
31 |
Yip D, Harper PG (2000). Predictive and prognostic factors in small cell lung cancer: current status. Lung cancer, 28, 173-85.
DOI
ScienceOn
|